{"id":"tp-32096","type":"article-newspaper","title":"UBS Resumes Regeneron Coverage at Buy, Citing Dupixent Follow-Ons","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/32096","datePublished":"2026-10-14T21:50:04.000Z","dateModified":"2026-10-14T21:50:04.000Z","language":"en","abstract":"The bank sees potential value in follow-on treatments to Dupixent and the potential to expand the drug’s exclusivity.","section":"Business","references":[]}